# Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06974110/  
OnCo record `nct06974110` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MOMA-341 run by MOMA Therapeutics, now recruiting.

## Summary

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06974110 by MOMA Therapeutics, with 132 participants planned, started 2025-07-16. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer and dMMR Cancer. Interventions recorded: MOMA-341, Irinotecan and Immunotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06974110
- Phase: 1
- Setting: A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors
- Sponsor: MOMA Therapeutics
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT06974110: https://clinicaltrials.gov/study/NCT06974110

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MOMA-341](https://onco.cc/drugs/moma-341/)
- companies: [MOMA Therapeutics](https://onco.cc/companies/moma-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06974110.json